|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Infliximab to treat severe ulcerative colitis显示文摘A 48-year-old female with severe ulcerative colitis refractory to conventional therapy was referred to our facility for management. The patient showed extensive ulcerative colitis since the age of 20 years and had failed therapy with 5-aminosalicylic acid agents and azathioprine. The disease remained active despite treatment with steroids and cyclosporine. The clinical and endoscopic parameters were consistent with severe disease. Infectious precipitants were ruled out. Given the severity of the disease and in order to avoid a colectomy, we started the patient on infliximab therapy. A dramatic clinical and endoscopic response was observed and she remained in remission at the end of a 1-year follow-up period. We discuss findings in the literature regarding the use ofinfliximab therapy in patients with ulcerative colitis who have failed steroids and cyclosporine. | Dídia Bisamra Cury Marcelo de Souza Cury Geraldo Vinicius Hemerly Elias Sender Jankiel Mizsputen | 2009 | World Journal of Gastroenterology2009，15，14： | 6 |
| 2 | Hepatic ischemic preconditioning increases portal vein flow in experimental liver ischemia reperfusion injury显示文摘BACKGROUND: Ischemic preconditioning(IPC) has been shown to decrease liver injury and to increase hepatic microvascular perfusion after liver ischemia reperfusion. This study aimed to evaluate the effects of IPC on hemodynamics of the portal venous system. METHODS: Thirty-two rats were randomized into two groups: IPC group and control group. The rats of the IPC group underwent IPC by 10 minutes of liver ischemia followed by 10 minutes of reperfusion before liver ischemia, and the rats of the control group were subjected to 60 minutes of partial liver ischemia. Non-ischemic lobes were resected immediately after reperfusion. The animals were studied at 4 hours and 12 hours after reperfusion. Mean arterial pressure, heart rate, portal vein flow and pressure were analyzed. Blood was collected for the determination of the levels of aspartate aminotransferase, alanine aminotransferase, calcium, lactate, pH, bicarbonate, and base excess. RESULTS: IPC increased the mean portal vein flow at 4 hours and 12 hours after reperfusion. IPC recovered 78% of the meanportal vein flow at 12 hours after reperfusion. IPC decreased the levels of aspartate aminotransferase, alanine aminotransferase and lactate, and increased the levels of ionized calcium, bicarbonate and base excess at 12 hours after reperfusion. CONCLUSIONS: This study demonstrated that IPC increases portal vein flow and enhances hepatoprotective effects in liver ischemia reperfusion. The better recovery of portal vein flow after IPC may be correlated with the lower levels of transaminases and with the better metabolic profile. | Estela RR Figueira Joel A Rocha-Filho Mauro Nakatani Marcelo FS Buto Eduardo R Tatebe Vitor O Andre Ivan Cecconello Luiz AC D'Albuquerque | 2014 | Hepatobiliary & Pancreatic Diseases International2014，13，1： | 6 |
| 3 | Fatty liver disease,an emerging etiology of hepatocellular carcinoma in Argentina显示文摘AIM To investigate any changing trends in the etiologies of hepatocellular carcinoma(HCC) in Argentina during the last years. METHODS A longitudinal cohort study was conducted by 14 regional hospitals starting in 2009 through 2016. All adult patients with newly diagnosed HCC either with pathology or imaging criteria were included. Patients were classified as presenting non-alcoholic fatty liver disease(NAFLD) either by histology or clinically, provided that all other etiologies of liver disease were ruled out, fatty liver was present on abdominal ultrasound and alcohol consumption was excluded. Complete follow-up was assessed in all included subjects since the date of HCC diagnosis until death or last medical visit.RESULTS A total of 708 consecutive adults with HCC were included. Six out of 14 hospitals were liver transplant centers(n = 484). The prevalence of diabetes mellitus was 27.7%. Overall, HCV was the main cause of liver disease related with HCC(37%) including cirrhotic and non-cirrhotic patients, followed by alcoholic liver disease 20.8%, NAFLD 11.4%, cryptogenic 9.6%, HBV 5.4% infection, cholestatic disease and autoimmune hepatitis 2.2%, and other causes 9.9%. A 6-fold increase in the percentage corresponding to NAFLDHCC was detected when the starting year, i.e., 2009 was compared to the last one, i.e., 2015(4.3% vs 25.6%; P < 0.0001). Accordingly, a higher prevalence of diabetes mellitus was present in NAFLD-HCC group 61.7% when compared to other than NAFLD-HCC 23.3%(P < 0.0001). Lower median AFP values at HCC diagnosis were observed between NAFLD-HCC and non-NAFLD groups(6.6 ng/m L vs 26 ng/m L; P = 0.02). Neither NAFLD nor other HCC etiologies were associated with higher mortality.CONCLUSION The growing incidence of NAFLD-HCC documented in the United States and Europe is also observed in Argentina, a confirmation with important Public Health implications. | Federico Pinero Josefina Pages Sebastián Marciano Nora Fernández Jorge Silva Margarita Anders Alina Zerega Ezequiel Ridruejo Beatriz Ameigeiras Claudia D’Amico Luis Gaite Carla Bermúdez Manuel Cobos Carlos Rosales Gustavo Romero Lucas McCormack Virginia Reggiardo Luis Colombato Adrián Gadano Marcelo Silva | 2018 | World Journal of Hepatology2018，10，1： | 4 |
| 4 | Nat Genet:单基因突变导致过敏性皮炎的发生显示文摘最近,研究者们鉴定出了一类导致神经性皮炎发生的关键基因突变:CARDll。来自美国NIH过敏与传染病研究所的研究者们通过对四个没有血缘关系的患病家庭进行分析,发现了这一导致疾病产生的基因、 | Chi A Ma, Yuan Zhang, Michael A Weinreich, Jonathan J Lyons, Celeste G Nelson, Thomas DiMaggio, Kelly D Stone, Joshua D Milner Jeffrey R Stinson, Elisa Ruffo, Batsukh Dorjbal, Swadhinya Arjunaraja, Kelsey Voss, Andrew L Snow Jordan K Abbott, Pia J Hauk, Paul R Reynolds, Erwin W Gelfand Elisa Ruffo Salomé Glauzy, Natsuko Yamakawa, Eric Meffre Jennifer Stoddard, Julie Niemela, Sergio D Rosenzweig Yu Zhang, Helen F Matthews Joshua J McElwee Nina Jones Alejandro Palma, Matías Oleastro, Emma Prieto, Andrea R Bernasconi, Geronimo Dubra, Silvia Danielian, Jonathan Zaiat, Marcelo A Marti Brian Kim Megan A Cooper Neil Romberg | 2017 | 现代生物医学进展2017，17，27： | 3 |
| 5 | Intermediate-advanced hepatocellular carcinoma in Argentina:Treatment and survival analysis显示文摘BACKGROUND Hepatocellular carcinoma(HCC) represents the sixteenth most frequent cancer in Argentina. The rise of new therapeutic modalities in intermediate-advanced HCC opens up a new paradigm for the treatment of HCC.AIM To describe real-life treatments performed in patients with intermediateadvanced HCC before the approval of new systemic options.METHODS This longitudinal observational cohort study was conducted between 2009 and2016 in 14 different regional hospitals from Argentina. Included subjects had intermediate-advanced Barcelona Clinic Liver Cancer(BCLC) HCC stages(BCLC B to D). Primary end point analyzed was survival, which was assessed for each BCLC stage from the date of treatment until last patient follow-up or death.Kaplan Meier survival curves and Cox regression analysis were performed, with hazard ratios(HR) calculations and 95% confidence intervals(95%CI).RESULTS From 327 HCC patients, 41% were BCLC stage B, 20% stage C and 39% stage D.Corresponding median survival were 15 mo(IQR 5-26 mo), 5 mo(IQR 2-13 mo)and 3 mo(IQR 1-13 mo)(P < 0.0001), respectively. Among BCLC-B patients(n =135), 57% received TACE with a median number of 2 sessions(IQR 1-3 sessions).Survival was significantly better in BCLC-B patients treated with TACE HR =0.29(CI: 0.21-0.40) than those without TACE. After tumor reassessment by RECIST 1.1 criteria following the first TACE, patients with complete response achieved longer survival (HR = 0.15(CI: 0.04-0.56, P = 0.005))Eighty-two patients were treated with sorafenib, mostly BCLC-B and C(87.8%). However,12.2% were BCLC-D. Median survival with sorafenib was 4.5 mo(IQR 2.3-11.7 mo);which was lower among BCLC-D patients 3.2 mo(IQR 2.0-14.1 mo). A total of 36 BCLC-B patients presented tumor progression after TACE. In these patients,treatment with sorafenib presented better survival when compared to those patients who received sorafenib without prior TACE [HR = 0.26(CI: 0.09-0.71);P= 0.013].CONCLUSION In this real setting, our results were lower than expected. This highlights unmet needs in Argentina, prior to the introduction of new treatments for HCC. | Federico Pinero Sebastián Marciano Nora Fernández Jorge Silva Margarita Anders Alina Zerega Ezequiel Ridruejo Gustavo Romero Beatriz Ameigeiras Claudia D’Amico Luis Gaite Carla Bermúdez Virginia Reggiardo Luis Colombato Adrián Gadano Marcelo Silva | 2019 | World Journal of Gastroenterology2019，25，27： | 3 |
| 6 | Dynamic localization of hepatocellular transporters in health and disease显示文摘Vesicle-based traffi cking of hepatocellular transporters involves delivery of the newly-synthesized carriers from the rough endoplasmic reticulum to either the plasma membrane domain or to an endosomal,submembrane compartment,followed by exocytic targeting to the plasma membrane. Once delivered to the plasma membrane,the transporters usually undergo recycling between the plasma membrane and the endosomal compartment,which usually serves as a reservoir of pre-existing transporters available on demand. The balance between exocytic targeting and endocytic internalization from/to this recycling compartment is therefore a chief determinant of the overall capability of the liver epithelium to secrete bile and to detoxify endo and xenobiotics. Hence,it is a highly regulated process. Impaired regulation of this balance may lead to abnormal localization of these transporters,which results in bile secretory failure due to endocytic internalization of key transporters involved in bile formation. This occurs in several experimental models of hepatocellular cholestasis,and in most human cholestatic liver diseases. This review describes the molecular bases involved in the biology of the dynamic localization of hepatocellular transporters and its regulation,with a focus on the involvement of signaling pathways in this process. Their alterations in different experimental models of cholestasis and in human cholestatic liver disease are reviewed. In addition,the causes explaining the pathological condition (e.g. disorganization of actin or actin-transporter linkers) and the mediators involved (e.g. activation of cholestatic signaling transduction pathways) are also discussed. Finally,several experimental therapeutic approaches based upon the administration of compounds known to stimulate exocytic insertion of canalicular transporters (e.g. cAMP,tauroursodeoxycholate) are described. | Marcelo G Roma Fernando A Crocenzi Aldo D Mottino | 2008 | World Journal of Gastroenterology2008，14，44： | 2 |
| 7 | Sequential assembly and polymerization of the polyprenol-linked pentasacchariderepeating unit of the Xanthan polysaccharide in Xanthomonas campestris显示文摘 | Luis I Roberto O C Marcelo A D | 1993 | Journal of Bacteriology1993，175，9： | 1 |
| 8 | Temporomandibular joint-preserving preauricular subtemporal-infratemporal fossa approach:surgical technique and clinical application显示文摘 | MARCELO D OBERT C | 2004 | Neurosurgery2004，55，1： | 1 |
| 9 | Clonal relationships among avian Escherichia coli isolates determined by enterobacterial repetitive intergenic consensus (ERIC) - PCR显示文摘 | WANDERLEY D D S ALESSANDRA F MARCELO L | 2002 | Veterinary Microbiology2002，89，： | 1 |
| 10 | Air stable ligandless heterogeneous catalyst systems based on Pd and Au supported in SiO 2 and MCM-41 for Suzuki–Miyaura cross-coupling in aqueous medium显示文摘 | Marcelo Gomes Speziali Anderson Gabriel Marques da Silva Débora Michelini Vaz de Miranda Adriano Lisboa Monteiro Patricia Alejandra Robles-Dutenhefner | 2013 | Applied Catalysis A General2013，，： | 1 |
| 11 | Nitric oxide:properties and therapeutic use显示文摘 | Ricardo de L B Carlos Roque D C Marcelo N M | 2005 | Quím Nova2005，28，6： | 1 |
| 12 | Particle swarm optimization applied to the nuclear reload problem of a pressurized water reactor显示文摘 | ANDERSON A M M MARCELO D M ROB- ERTO S | 2009 | Annals of Nuclear Energy2009，51，2： | 1 |
| 13 | The conservation value of linear forest remnants in central Amazonia 显示文摘 | Marcelo G D Claude Gascon | 1999 | Biological Conservation1999，，91： | 1 |
| 14 | The fuzzy clearing approach for a niching genetic algorithm applied to a nuclear reactor core design optimization problem显示文摘 | SACCO W F MARCELO D M CLAUDIO M N A | 2004 | An- nals of Nuclear Energy2004，31，1： | 1 |
| 15 | Plant functional traits and environmental filters at a regional scale显示文摘 | Sandra D Marcelo C Fernado C | 1998 | Journal of Vegetation Science1998，9，： | 1 |
| 16 | Hesperidin exerts antidepressant-like effects in acute and chronic treatments in mice: possible role of pathway and BDNF levels 1-arginine-NO-cGMP 显示文摘 | D Franciele DG Marcelo Gomes ATR Goes | 2014 | Brain ResearchBulletin2014，104，： | 1 |
| 17 | Synthesis, surface - active properties, and antimicrobial activities of new neutral and cationic trimeric surfactants 显示文摘 | MARCELO C M MARIANO D C AYELEN P | 2008 | Journal of Surfactants and Detergents2008，11，1： | 1 |
| 18 | Sequential assembly and polymerization of the polyprenol-linked pentasaccharide repeating unit of the Xanthan polysaccharide in Xanthomonas campestris显示文摘 | Luis I Roberto O C Marcelo A D | 1993 | Journal of Bacteriology1993，175，9： | 1 |
| 19 | Serologic marker candidates identified among B-cell linear epitopes of Nsp2 and structural proteins of a North American strain of porcine reproductive and respiratory syndrome virus 显示文摘 | Marcelo d L Asit K P Eduardo F F | 2007 | Virology2007，353，2： | 1 |
| 20 | New aluminosilicate and titanosilicate delaminatedmaterials active for acid catalysis and oxidation reactionsusing H2O2显示文摘 | AVELINO C URBANO D MARCELO E D | 2000 | J Am Chem Soc2000，122，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员